Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Last updated: April 20, 2018
Sponsor: Sherief Abd-Elsalam
Overall Status: Active - Not Recruiting

Phase

3

Condition

Gastrointestinal Diseases And Disorders

Hemorrhage

Ulcers

Treatment

N/A

Clinical Study ID

NCT03388125
Active bleeding
  • All Genders

Study Summary

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • cirrhotic patients presented with actively bleeding

Exclusion

Exclusion Criteria:

  • other sources of UGIB than esophageal varices, hepatic encephalopathy orhepatocellular carcinoma (HCC)

Study Design

Total Participants: 113
Study Start date:
January 01, 2016
Estimated Completion Date:
December 01, 2022

Study Description

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Connect with a study center

  • Sherief Abd-Elsalam

    Tanta,
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.